MLchartDataset catalogue

Hercessi

Term · Oncology and biomedicine · MLC-T-ONC-003840

A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2 positive. It is also being studied in the treatment of other types of cancer. Hercessi binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Hercessi is a type of monoclonal antibody and a type of HER2 receptor antagonist. Also called Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, trastuzumab, and Trazimera.

Table 1. Record
IdentifierMLC-T-ONC-003840
FieldOncology and biomedicine
SynonymsHerceptin; Herzuma; Kanjinti; Ogivri; Ontruzant; trastuzumab; Trazimera
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-003840",
  "term": "Hercessi",
  "field": "Oncology and biomedicine",
  "definition": "A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2 positive. It is also being studied in the treatment of other types of cancer. Hercessi binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Hercessi is a type of monoclonal antibody and a type of HER2 receptor antagonist. Also called Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, trastuzumab, and Trazimera.",
  "synonyms": [
    "Herceptin",
    "Herzuma",
    "Kanjinti",
    "Ogivri",
    "Ontruzant",
    "trastuzumab",
    "Trazimera"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/hercessi/"
}

Record 8,442 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.